PYC: Multiple clinical readouts and a strong safety profile drive momentum toward late-stage trials
Upcoming 18 months will see multiple human safety and efficacy readouts across four clinical programs, with the PKD program advancing toward registrational studies and showing a clean safety profile so far. Organizational expansion and capital strength position the company for late-stage developmen…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.